Bullish Moving Averages
9
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Open Price
1385.00Prev. Close
1398.7500Volume
245487.00Value
346247139.15Fundamentals
Market Cap
26671.40
Price to Earnings
0.00
Price to Book Value
8.50
Dividend Yield
0.00
PE to Growth
0.00
Op Revenue TTM
0.00
Net Profit TTM
0.00
Cash From Operating Activity
1097.24
Return on Equity %
16.87
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
04 Sep, 2024
62
Week
62.3
Month
51.8
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
1409.48
PIVOT
First Resistance
1433.97
Second Resistance
1457.48
Third Resistance
1481.97
First Support
1385.97
Second Support
1361.48
Third Support
1337.97
Relative Strength Index
61.08
Money Flow Index
81.89
MACD
21.19
MACD Signal
10.96
Average True Range
46
Average Directional Index
31.21
Rate of Change (21)
12.84
Rate of Change (125)
Commodity Channel Index
84.2
Williams %R
-21.5
BETA
1 Month
1.18
3 Month
1 Year
3 Year
PRICE CHANGE ANALYSIS
↑ 1.55%
1 Week
Low
High
1359.5
1433
↑ 8.64%
1 Month
Low
High
1225
1455.2
↑ 39.93%
3 Months
Low
High
1225
1455.2
↑ 39.93%
6 Months
Low
High
1225
1455.2
↑ 39.93%
1 Year
Low
High
1225
1455.2
19 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated August 8, 2024, please find enclosed the transcript of the Earnings Call for the Q1 FY25, held on Wednesday, August 14, 2024 at 8.30 a.m. (IST).
15 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Unaudited Financial Results of the Company for the quarter ended June 30, 2024, as published in the newspapers viz. "Financial Express" and "Loksatta" on August 15, 2024.
14 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated August 8, 2024, regarding earnings call, the audio recording of the call held today is available on our website.
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Outcome Of Board Meeting Held On August 13, 2024
Outcome of Board Meeting held on August 13, 2024
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Outcome Of Board Meeting Held On August 13, 2024
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Unaudited Financial Results for the quarter ended June 30, 2024, along with the Limited Review Reports on the aforesaid results as issued by the B S R & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the aforesaid results are enclosed as Annexure B.
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2024
The Board of Directors of the Company at its meeting held today i.e. Tuesday, August 13, 2024 has inter-alia approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, as reviewed and recommended by the Audit Committee. Pursuant to Regulation 33 of the Listing Regulations, we are enclosing herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, along with the Limited Review Reports on the aforesaid Results as issued by B S R & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, is also enclosed herewith as Annexure B.
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 read with Para A of Part of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that CARE Ratings Limited ("CARE"), has upgraded its ratings on the Bank Facilities of Emcure Pharmaceuticals Limited ("the Company"), vide its press release as received by the Company on August 13, 2024.
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025, as amended, we wish to inform that CRISIL Ratings Limited ("CRISIL") has upgraded its ratings on the Bank Loan Facilities of Emcure Pharmaceuticals Limited.
08 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation for Earnings Call for Investors/ Analysts to be held on Wednesday, August 14, 2024 at 8.30 a.m. (IST) to discuss the Company''s unaudited financial results (standalone and consolidated) and performance for the quarter ended June 30, 2024.
06 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2024
Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2024.
